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Abstract
Beta-3 adrenergic receptors have important physiological implications, being expressed
in many places in the body, including brown adipose tissue. Of the effects studied in
preclinical research on lipid metabolism attributable to stimulation of these receptors, we
can mention the increased thermogenesis and metabolic rate in the brown adipose tissue,
reduction of  body weight  in  obese  diabetic  rats,  lowering of  intra-abdominal  and
subepithelial fat in nonobese and nondiabetic rats, decrease of triglyceride, and increase
of HDL cholesterol levels. Carbohydrate metabolism is also changed by beta-3 adrenergic
agonists,  the  most  prevalent  effects  being blood glucose lowering in  diabetic  rats,
increasing insulin secretion of the pancreas, or increasing glucose tolerance. Metabolic
effects of 13 newly synthesized compounds of beta-phenylethylamine structure and
reference BRL 37344 were investigated in order to identify a potential affinity for beta-3
adrenergic receptors. The antidiabetic and hypolipemiant effects were investigated on a
rat  model  of  alloxan-induced  diabetes.  The  results  demonstrated  that  new  beta-
phenylethylamine derivatives produced marked biological activity over lipid profile. All
compounds have markedly decreased the values of total cholesterol, LDL cholesterol,
and triglycerides and also have increased the values of antiatherogenic HDL cholesterol.
The effects were significantly more intense than the reference substance BRL 37344.
Keywords: beta-3 adrenergic agonists, antidiabetic, hypolipemiant, glucose-6-phos-
phate dehydrogenase, glucose-6-phosphatase, hexokinase, beta-phenylethylamine
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1. Introduction
The sympathetic nervous system is part of the autonomic nervous system and innervates
tissues in almost every organ system. Adrenergic system is important for maintaining the
organism homeostasis and mediates the neuronal and hormonal stress response commonly
known as the fight-or-flight response.
Central and peripheral adrenergic neurotransmitters are epinephrine and norepinephrine,
which act on their specific adrenergic receptors.
Adrenergic receptors types
and subtypes
Tissue localization Dominant effects
α-Adrenergic
receptors 
α1A Heart, blood vessels, smooth muscle, liver,
lung, vas deferens, prostate, cerebellum,
cortex, hippocampus
Contraction of vascular smooth muscle;
vasoconstriction of large resistant
arterioles in skeletal muscle
α1B Heart, kidney, spleen, lung, blood vessels,
cortex, brainstem
Promotes cardiac growth and structure
α1D Aorta, coronary artery, platelets, prostate,
cortex, hippocampus
Vasoconstriction in aorta and coronary
artery
α2A Sympathetic neurons, platelets, pancreas,
locus coeruleus, brainstem, spinal cord
Main inhibitory receptor on sympathetic
neurons
α2B Liver, kidney, pancreas, blood vessels Mediates α2 vasoconstriction
α2c Basal ganglia, cortex, cerebellum,
hippocampus
Modulates dopamine neurotransmission




β1 Heart, kidney, skeletal muscle, cortex,
olfactory nucleus, brain stem
Positive inotropic and chronotropic
effects
β2 Bronchial and gastrointestinal smooth
muscle, blood vessels, heart, lung, skeletal
muscle, cortex
Smooth muscle relaxation, skeletal
muscle hypertrophy
β3 Adipose tissue, gastrointestinal tract,
gallbladder, urinary bladder
Lipolysis, thermogenesis, relaxation of
the bladder
Tissue localization and dominant effects (after Goodman & Gillman’s 2011, modified).
Table 1. Types and subtypes of adrenergic receptors.
Adrenergic receptors were described for the first time by Ahlquist in 1948, who hypothesized
the existence of two different types of receptors, α and β, based on the consideration that
adrenaline, noradrenaline, and other pharmacological agonists regulate various physiological
functions [1]. This differentiation of receptors was confirmed by the finding that there are
antagonists, which selectively block α receptors (e.g., phenoxybenzamine or phentolamine) or
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β receptors (e.g., propranolol). Every type of adrenergic receptors has different subtypes,
which are mentioned in Table 1 [2–4].
1.1. Beta-3 adrenergic receptor discovery and structure
In the early 1980s, Tan S and Curtis-Prior PB proposed the term of beta-3 or beta-hybrid
receptor for a new type of beta-adrenergic receptor, based on some studies of four beta-
adrenergic agonists on isolated rat adipose cells. They observed that lipolytic potency de-
creased in the order: isoprenaline (beta-1 and beta-2 agonist) > noradrenaline (beta-1 >>> beta-2
agonist) > salbutamol (beta-2 agonist) > prenalterol (beta-1 agonist). They also studied the
effects of some beta-antagonists on lipolysis induced by various agonists. Propranolol
(nonselective beta-antagonist) was more potent than betaxolol (selective beta-1 antagonist) or
ICI 118551 (selective beta-2 antagonist). All results conducted to the idea that lipolysis in
adipose tissue is regulated by other adrenergic receptor than the classical ones, beta-1 and
beta-2 [5].
In 1989, Emorine et al. first characterized beta-3 receptor by discovering the gene that enco-
des it [6]. Before that Arch et al. observed that some nonspecific classical beta-receptor agonists,
named BRL 26830A, BRL 33725A, and BRL 35135A, had antiobesity actions on obese and
diabetic mice [7].
Further studies have shown that beta-3 receptor is different than beta-1 and beta-2 by some
important issues:
– the specific agonists CL 316243 and BRL37344 stimulate only beta-3 receptor [8, 9];
– lack of beta-3 receptor desensitization after agonists activation [10]; and
– the need to use larger quantities of catecholamines to stimulate beta-3 receptors [11].
The structures of beta-1, beta-2, and beta-3 receptors are similar, being all members of G
protein-coupled receptors. Beta-3 receptor is a protein which contains 396 amino acids, found
in seven transmembrane segments, with three intracellular and three extracellular loops. The
amino-terminal region is extracellular, glycosylated, and with variable length. The carboxyl-
terminal region is intracellular and it does not possess phosphorylation sites, which are present
at beta-1 and beta-2 receptors. Essential for interaction with the ligands are the disulfide bond
between the second and the third extracellular loops and also four of the seven transmembrane
segments. Other two segments are implicated in G-protein stimulation, with adenylate cyclase
and second messenger activation [12].
1.2. Metabolic effects of beta-3 adrenergic receptor stimulation
Some of the most important effects of beta-3 receptor activation are the metabolic ones,
especially in the brown adipose tissue. This thermogenic tissue has the role of keeping
constant body core temperature of small animals at cold ambient temperatures. Stimulation
of beta-3 adrenergic receptors not only activates brown adipose tissue thermogenesis in the
short term, but also increases mitochondrial biogenesis and the expression of thermogenin
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(UCP1) [13–15]. This protein mediates transport across the internal mitochondrial membrane
and interrupts oxidative phosphorylation of the beta oxidation of fatty acids, increasing the
use of energy [16]. There have been investigations about the effects of beta-3 adrenergic
agonists on thermogenin. The results have shown that beta-3 agonists activated thermogenin,
and also other uncoupling proteins, as follows:
• UCP2 that is found in many tissues.
• UCP3 that is found in skeletal muscle and has an important role in basal thermogenesis [17].
The stimulation of thermogenesis by beta-3 adrenergic agonists resulted in a number of
experimental studies, which have shown that in animals, these substances lead to weight loss,
a selective fat decrease, but without reducing food intake [18].
An in vitro study was performed on cells with high levels of beta-3 adrenoreceptors such as
the adipocytes of the murine cell line 3T3-F442A. The study demonstrated that insulin and
glucocorticoids downregulate beta-3 adrenoreceptor expression through a transcriptional
effect. The impairment of beta-3 adrenoceptor gene expression in adipocytes of congenitally
obese ob/ob mice could be related to the higher glucocorticoid plasma levels when compared
to lean mice [19].
The main studied metabolic actions in preclinical research of beta-3 adrenergic agonists were
the reduction of plasma insulin levels, increase glucose tolerance, and reducing body weight
in obese diabetic rats. The major implication of beta-3 adrenergic receptor in glucose metabo-
lism and hence in the release of insulin and in obesity has been demonstrated [20, 21].
The development of beta-3 adrenergic agonists was a step forward for the treatment of
metabolic diseases by sympathetic activation, because norepinephrine and other relative
nonselective derivatives have cardiovascular side effects which limit their use.
1.3. Preclinical studies of beta-3 agonists on carbohydrate and lipid metabolism
Numerous nonclinical studies have shown that administration of beta-3 agonists decreased
glucose and lipids plasma concentrations in diabetic mice derived from genetically modified
strains (kk, C57BL/KsJ- db/db) or in rats with experimentally induced diabetes [22, 23].
Several mechanisms of action were highlighted and reported:
– improving insulin resistance and increased tissue response to insulin [24],
– increasing insulin secretion in beta cells of the pancreas [25],
– decrease in glucose release from the liver, increase noninsulin-dependent uptake of
glucose from white and brown adipose tissue and skeletal muscles [26], and
– increase of glucose tolerance at doses lower than those that stimulate lipolysis in adipose
tissue, without affecting the amount of food intake or body weight [27].
The nonclinical research for proving the effects of beta-3 agonists on obesity were conducted
on rodent species [28–30] from various strains, both normal and genetically modified to
generate predisposition to obesity.
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Studies in obese rats treated with the selective beta-3 adrenergic agonists have shown a
significant reduction in body weight and reduction of adipose tissue, without food intake being
affected by them. It was also demonstrated that an increase of two to three times of the mRNA
level and of UCP-type protein, as well as of the guanidine 5'-diphosphate coupled, a relevant
index of thermogenesis, in brown and white adipose tissues for the tested rats. In addition, it
has been found, after the administration of beta-3 adrenergic agonists, an improvement of
glucose tolerance and a decrease of hyperinsulinemia. The researchers suggested two possible
mechanisms for defining this aspect, increase of the number of insulin receptors or decrease
of glucose transporters in brown and white adipose tissues, which implies an increase in
glucose uptake into muscle tissue [31].
Lorente Ferrer et al. investigated the effect of beta-3 receptors agonists on thermogenesis in
deep adipose tissue. In general, these agonists increase energy consumption but their effects
are quickly counteracted by glucocorticoids. Thus, their potential for long-term treatment of
obesity is reduced. Since the metabolic effects of beta-3 receptor agonists (β3A) overlap only
partially with those of oleoyl-estrone (OE) (loss of appetite, weight change, loss of body fat),
the possibility of combining them in the energy balance in order to accelerate the decrease of
fat deposits was studied. Rats receiving OE or OE + β3A significantly reduced weight compared
with the control group, the maximum reduction corresponding to the group which received
the combination [32].
The effect of beta-3 adrenergic receptor agonists was investigated on two strains of rats with
different genetic predisposition to obesity: male rats aged 8 weeks Osborne Mendel (OM) strain
and S5B/P1 (S5B) strain. Animals were treated with beta-3 adrenergic agonist CL316243 after
they have been adapted to either a high fat diet (56% fat-based energy) or low fat (10% fat-
based energy), but both equivalent diets in terms of protein content (24% based on protein
energy). The animals were fed ad libitum and were injected with CL316243 in three doses: 0.1;
0.3; and 3 mg/kg at the beginning of the night. Food intake was measured at 1, 3, and 24 hours
after injection. The results showed that CL316243 significantly reduced food intake for all
measurements, in both types of rats. Inhibition of food intake was still higher in S5B-type mice.
CL316243 significantly decreased serum leptin and serum glucose at both types of rats,
especially at S5B. In OM rats, beta-3 adrenergic agonist increased serum insulin levels, while
in S5B rats fed with a low-fat diet, the level of serum insulin decreased. In another experiment,
CL316243 was administered to rats kept fasting overnight. It was observed after 30 minutes a
significant reduction in insulin levels in both types, more pronounced in S5B. The glucose level
in OM rats decreased after 30 and 60 minutes, while in rats S5B a decrease was observed only
after 30 minutes from the administration. Experiments have shown that beta-3 agonist
CL316243 has a much more obvious effect on rat strain resistant to obesity induced by high-
fat diet [33].
Another study used a transgenic model of mice, lacking beta-3 adrenergic receptors. CL316243
blocked the activation of adenylate cyclase and lipolysis when it was administered to these
mice. A modest growth of fat tissues especially in females was observed. These mice showed
an increase in the level of mRNA for beta-1 receptor, but not for receptor beta-2. This showed
a functional compensation between the genes for beta-1 and beta-3 receptors. Finally, a sharp
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increase of insulin levels and lipolysis after administration of CL316243 in normal mice was
noted; effects were not found after administration of beta-3 adrenergic agonists in beta-3
receptor-deficient mice [34].
In another model of knockout mice lacking functional beta-3 adrenoreceptors, there were no
responses for food intake and insulin secretion in white and brown adipocytes after adminis-
tration of beta-3 adrenergic agonist CL316243, indicating the implication of beta-3 receptors in
these metabolic effects [35].
An increase in insulin levels during “fasted/fed” transition in rats has been demonstrated,
associated with a decrease in the mRNA level of beta-3 adrenergic receptor and a decrease of
the response in brown and white adipose tissues. It was concluded that there is a close
relationship between the food intake, plasma levels of insulin, and beta-3 adrenergic receptors.
Downregulation of the beta-3 receptors could be a possible mechanism by which insulin
determines lipid storage and prevents lipid mobilization after food intake [36].
In another study, CL316243 was administered in obese diabetic KKAy mice for 2 weeks. The
results showed a decrease of serum levels of glucose, insulin, triglyceride, free fatty acid, and
tumor necrosis factor-alpha (TNF-alpha) and an increase of adiponectin. The beta-3 adrenergic
receptor agonist recovered the mRNA expressions of adiponectin, adiponectin receptors, and
beta-3 adrenoreceptor, which were reduced in epididymal white adipose tissue in KKAy mice.
Also, CL316243 suppressed the overexpressed mRNA level of TNF-alpha in both epididymal
white and brown adipose tissues. It was concluded that the normalization of adiponectin,
adiponectin receptors and TNF-alpha could contribute at the amelioration of obesity-induced
insulin resistance [28].
In the study conducted on nonobese/nondiabetic Sprague-Dawley rats, the selective beta-3
agonist CL 312243 increased food intake, metabolic rate, and body temperature after 7 days of
treatment. The author also showed a decrease in intra-abdominal and subepithelial fat, a
hepatic glucose level independent of variations in body weight, an increase in interscapular
fat, and in total glucose, which stimulates the production of insulin. According to the results,
only white and brown adipose tissues have been affected. A more important role of adipose
tissue in glucose uptake underlining the potential role of beta-3 adrenergic agonist drugs for
the treatment of obesity and insulin-resistant diabetes was suggested [8].
By a critical analysis of the published data in nonclinical research, it was concluded that beta-3
adrenergic receptor activation in the experiment-induced diabetes and obesity [37, 38]
determines an increase of glucose tolerance and lipolysis activation in adipose tissue [22]. It
seems that the effects are dose dependent and the selectivity of actions for glucose metabolism
occurs at lower doses than those used for influencing lipid metabolism.
Comparing the effects of beta-3 agonists in rats and humans, Arch and Wilson stated that these
compounds, with remarkable effects on rodents, have not convinced in clinical studies because
of limited efficacy or serious side effects. The explanations mentioned by the authors included
low pharmacokinetic properties and a low biotransformation to active compounds. A possible
more important distinction between rats and humans is the different structure of beta-3
receptors, leading to lower efficacy of compounds in humans than in rats. In addition, it seems
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that the number of beta-3 receptors is lower than beta-1 and beta-2 receptors in the tissues that
mediate thermogenesis in humans [39]. This is one of the reasons why the clinical studies
conducted on beta-3 selective agonists had some contradictory results.
Mirabegron, a currently approved drug for the treatment of overactive bladder, was recently
studied in humans for its effects on brown adipose tissue. This drug has several advantages
over other members of its class, including a higher bioavailability and a higher in vitro affinity
for the human beta-3 adrenoreceptor. Mirabegron was orally administered in the dose of 200
mg to 12 healthy male subjects with detectable brown adipose tissue. The results showed that
all treated subjects had a higher brown adipose tissue metabolic activity, measured with 18F-
fluorodeoxyglucose (18F-FDG) using positron emission tomography (PET) combined with
computed tomography (CT). These are promising results for a possible future use of beta3
agonists for metabolic disease [40].
Based on all these preclinical and clinical considerations new chemical entities with beta-
phenylethylamine nucleus, substituted in various positions on the nucleus or side chain, with
potential action on diabetes and/or obesity were synthesized [41, 42]. Chemists led synthesis
in order to obtain derivatives with increased beta-3 receptor selectivity. The compounds were
conventionally named A1-βPhEA–A13-βPhEA (Figure 1).
Figure 1. General structure of the newly synthesized compounds. X = H, alkoxy, halogen, dihalogen; Y = 4-carbopro-
poxy-phenoxy, 4-carbomethoxymethylene-phenoxy, 4-carbomethoxyethylene-phenoxy.
2. Objectives
The purpose of this study was to test the effects of the newly synthesized compounds over
lipid profile and body weight of rats to which alloxanic diabetes was induced, being a known
fact that this metabolic disorder induces alterations in plasma lipids.
Alloxan was chosen for induction of type II diabetes mellitus because its pancreatic toxicity
was demonstrated in nonclinical trials using isolated islet cell or entire perfused rat pancreas
and afterwards by directly administering the substance to rodent or nonrodent animals. In the
first stage, alloxan stimulates on short-term insulin secretion, which is followed by total
suppression of the response of the islet cells to glucose, regardless of its concentration [43].
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Alloxan is readily absorbed by beta pancreatic cell, a process that contributes to diabetogenic
action. Its absorption also takes place in liver although hepatocytes are more resilient to its
action compared to beta cells, therefore more protected against its toxicity [44].
2.1. Mechanism of alloxan toxicity
The mechanism of toxic action resides in formation of reactive species of oxygen [45], the
alloxan exhibiting increased affinity to substrates containing thiolic groups (reduced gluta-
thione, cysteine, proteins with sulfide groups, enzymes) [46]. The product of alloxan reduction,
the dialuric acid, is reoxidized to alloxan, the redox cycle thus formed being responsible for
releasing superoxide radicals—see Figure 2 [47].
Figure 2. Mechanism of diabetes induction by administration of alloxan [47]. A, Alloxan; AH·, alloxan radical; AH2,
dialuric acid; O2·-, superoxide radical; OH·, hydroxyl radical.
An optimal protection against cytotoxic action of alloxan and dialuric acid is offered by an
association between superoxide-dismutase (SOD) and catalase (CAT), in order to completely
prevent the redox cycle and consecutively the formation of any reactive oxygen species [48].
Glucose confers complete protection against toxic effects of alloxan both in vivo and in vitro,
by blocking glucokinase inhibition by it and also contributing to maintaining the antioxidant
protection mechanism of the beta cells [49].
One of the targets for the reactive oxygen species is the DNA of the pancreatic islet cells. The
DNA fragmentation occurs in beta cells exposed to alloxan [49, 50].
The DNA alteration stimulates poly-ADP-ribose, enzyme which contributes to affected DNA
repair. In several trials it was stated that glucose administration contributes to counteracting
the alloxan cytotoxicity. Such ability is the result not only of glucokinase protection but also of
interaction with glucose carrier GLUT2 resulting in reduced alloxan absorption [51].
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3. Materials and methods
Diabetes was induced to white Wistar male rats by intraperitoneal administration of extem-
poraneously prepared alloxan (Sigma-Aldrich) solution, in the dose of 130 mg/kg weight [52].
After 48 hours, glycemia was determined using ACCU-CHEK Active device (Roche Diagnos-
tics GmbH, D-68298 Mannheim, Germany). The blood was harvested from tail veins by vein
puncture. The determination was used for the selection of diabetic animals, thus presenting a
glycemia over 200 mg/dL.
From the total rat collectivity, a percentage of 66.34% became diabetic with the remaining
33.66% becoming hyperglycemic. Fifteen groups of diabetic animals were designated for
experimental research (eight animals/group), being treated as follows:
• diabetic control group (D Control)—distilled water, 1 mL/100 g weight p.o.;
• reference group—BRL 37344, 50 mg/kg weight, p.o.;
• A1-βPhEA—20 mg/kg weight, p.o.;
• A2-βPhEA—50 mg/kg weight, p.o.; and
• A3-βPhEA through A13-βPhEA, 100 mg/kg weight, p.o.
At the same time, a nondiabetic control group was designated (ND control), treated with
distilled water, 1 mL/100 g weight p.o. Administration of tested and reference substances (BRL
37344) continued for 14 days, once daily.
The doses chosen for investigating the metabolic effects of the newly synthesized derivatives
were established following previous determinations of acute toxicity which allowed to set
the LD50 [53, 54].
At the end of the experiment, the animals were sacrificed and biochemical and enzymatic
determinations were performed: glycemia, glucose-6-phosphate dehydrogenase (transform-
ing glucose by pentose-phosphate pathway), glucose–6–phosphatase (catalyzes the hydrolysis
of glucose–6–phosphate to glucose and inorganic phosphate), hexokinase (catalyzes the
phosphorylation of glucose), total cholesterol, LDL cholesterol, HDL cholesterol, and trigly-
cerides.
4. Results and discussion
The model of alloxan-induced diabetes has produced alterations in the activity of the three
enzymes [55–57] involved in glucose metabolism homeostasis (Figure 3).
Moreover, the lipid profile was altered by the administration of the pancreatic toxic, registering
statistically significant increases in total cholesterol, LDL cholesterol, and triglycerides,
together with decreases in HDL cholesterol (Figure 4).
New Potential Beta-3 Adrenergic Agonists with Beta-Phenylethylamine Structure, Synthesized for the Treatment...
http://dx.doi.org/10.5772/65328
227
Figure 3. Variations of the activity of the enzymes involved in glucose metabolism in diabetic animals compared to
nondiabetic animals.
Figure 4. Variation of plasma lipids in diabetic animals compared to nondiabetic animals ** p<0.01; *** p<0.001.
To what concern the effect of new compounds with possible affinity for beta-3 adrenergic
receptors, seven of those (A1-βPhEA, 20 mg/kg weight; A3-βPhEA, 100 mg/kg weight; A4-
βPhEA, 100 mg/kg weight; A6-βPhEA, 100 mg/kg weight; A8-βPhEA, 100 mg/kg weight; A9-
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βPhEA, 100 mg/kg weight; A13-βPhEA, 100 mg/kg weight) have markedly reduced the values
of total cholesterol (Table 2, Figure 5).




Nondiabetic control 78.22 ± 9.553  0.0002***  <0.0001*** **
Diabetic control 119.3 ± 11.89 **
BRL 37344 50 mg/kg  77.65 ± 2.196 ns *
A1-βPhEA 20 mg/kg  62.03 ± 5.005 ns ***
A2-βPhEA 50 mg/kg  74.83 ± 13.10 ns *
A3-βPhEA 100 mg/kg  70.42 ± 9.716 ns **
A4-βPhEA 100 mg/kg  69.27 ± 6.423 ns **
A5-βPhEA 100 mg/kg  113.0 ± 11.41 ns ns
A6-βPhEA 100 mg/kg  61.00 ± 4.749 ns ***
A7-βPhEA 100 mg/kg  75.05 ± 5.286 ns *
A8-βPhEA 100 mg/kg  72.31 ± 6.148 ns **
A9-βPhEA 100 mg/kg  69.25 ± 6.542 ns **
A10-βPhEA 100 mg/kg  77.73 ± 7.884 ns *
A11-βPhEA 100 mg/kg  66.60 ± 3.331 ns *
A12-βPhEA 100 mg/kg  75.32 ± 5.966 ns *
A13-βPhEA 100 mg/kg  62.15 ± 6.673 ns **
Table 2. The effect of new derivatives of beta-phenylethylamine on total cholesterol in rats with alloxan-induced
diabetes * p<0.05; ** p<0.01; *** p<0.001.
Figure 5. Alterations of total cholesterol in diabetic animals treated with reference substance (BRL 37344) or newly syn-
thesized derivatives of beta-phenyl ethylamine compared to diabetic control group * p<0.05; ** p<0.01; *** p<0.001.
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The majority of the tested compounds (Table 3) have markedly reduced the values of LDL
cholesterol (Figure 6), the effect probably due to increased plasma clearance for this lipid
fraction as total cholesterol serum concentration decreased. Smaller reductions, still statisti-
cally significant (Table 3) in values of LDL cholesterol, and comparable to those of the
beta-3adrenergic agonist, BRL 37344, were produced by the compounds: A7-βPhEA, A10-
βPhEA, A12-βPhEA, and A13-βPhEA (Figure 6).




Nondiabetic control  51.07 ± 3.610 <0.0001***   <0.0001*** *** 
Diabetic Control  103.2 ± 7.899  ***   
BRL 37344 50 mg/kg  78.71 ± 4.940  ns  ** 
A1-βPhEA 20 mg/kg  56.87 ± 1.887  ns  *** 
A2-βPhEA 50 mg/kg  57.47 ± 2.831  ns  *** 
A3-βPhEA 100 mg/kg  50.91 ± 1.205  ns  *** 
A4-βPhEA 100 mg/kg  57.08 ± 2.302  ns  *** 
A5-βPhEA 100 mg/kg  56.26 ± 2.134  ns  *** 
A6-βPhEA 100 mg/kg  56.88 ± 2.496  ns  *** 
A7-βPhEA 100 mg/kg  75.91 ± 6.447  **  *** 
A8-βPhEA 100 mg/kg  54.62 ± 2.458  ns  *** 
A9-βPhEA 100 mg/kg  53.70 ± 2.128  ns  *** 
A10-βPhEA 100 mg/kg 76.00 ± 7.567  **  *** 
A11-βPhEA 100 mg/kg 57.52 ± 3.112  ns  *** 
A12-βPhEA 100 mg/kg 66.77 ± 7.334  ns  *** 
A13-βPhEA 100 mg/kg 50.21 ± 1.188  ns  *** 
Table 3. The effect of new derivatives of beta-phenylethylamine on LDL cholesterol values in alloxan-induced diabetic
rats ** p<0.01; *** p<0.001.
Figure 6. Alterations of LDL cholesterol values in diabetic animals treated with reference substance (BRL 37344) or
new derivatives of beta-phenylethylamine compared to diabetic control group ** p<0.01; *** p<0.001.
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The results for lowered total cholesterol and LDL cholesterol are in line with other literature
data showing that several beta-3adrenergic agonists have induced similar effects in mice with
apolipoprotein E deficiency and in wild C57BL/6J strain animals. For such substances an
increase in apolipoprotein A1 and PPARα and PPARγ receptors (peroxisome proliferator-
activated receptor) expression in liver was demonstrated [58].
Other trials showed that, due to effects on lipid metabolism but also to glycemia reduction,
the β3 adrenergic agonist BRL 37344 has induced a reduction in the process of formation of
atherosclerotic plaque in ApoE(-/-) mice [59].
A pivotal role in slowing down the process of atherosclerosis stands with HDL cholesterol,
which is a small size alpha-lipoprotein, formed in liver or shed from chylomicrons dismem-
berment. These lipoproteins have a cholesterol-rich core with type 1 and 2 apolipoproteins at
the surface, ensuring the reverse transport of cholesterol, from tissues to liver. The trial
conducted by Shi et al. demonstrated the increases in mARN and apoA1 expression.




Nondiabetic control  46.36 ± 2.930 <0.0001***   <0.0001*** *** 
Diabetic control  29.34 ± 3.478  ***   
BRL 37344 50 mg/kg  34.82 ± 3.216  ns  ns 
A1-βPhEA 20 mg/kg  48.09 ± 3.621  ns  *** 
A2-βPhEA 50 mg/kg  42.96 ± 2.102  ns  * 
A3-βPhEA 100 mg/kg  46.24 ± 4.104  ns  *** 
A4-βPhEA 100 mg/kg  53.35 ± 4.875  ns  *** 
A5-βPhEA 100 mg/kg  49.79 ± 2.926  ns  *** 
A6-βPhEA 100 mg/kg  46.07 ± 3.679  ns  *** 
A7-βPhEA 100 mg/kg  52.18 ± 3.653  ns  *** 
A8-βPhEA 100 mg/kg  51.04 ± 1.662  ns  *** 
A9-βPhEA 100 mg/kg  47.81 ± 4.664  ns  *** 
A10-βPhEA 100 mg/kg 45.66 ± 4.880  ns  *** 
A11-βPhEA 100 mg/kg 38.04 ± 2.596  ns  ns 
A12-βPhEA 100 mg/kg 38.46 ± 2.095  ns  ns 
A13-βPhEA 100 mg/kg 41.94 ± 1.330  ns  * 
Table 4. The effect of new derivatives of beta-phenyl ethylamine on HDL cholesterol in rats with alloxan-induced
diabetes * p<0.05; *** p<0.001.
The results of the experimental research have shown that all tested compounds have induced
statistically significant increases in HDL cholesterol, compared to diabetic control group (Table
4). A smaller effect of increase of the values for this lipid fraction was produced by the
compounds A11-βPhEA and A12-βPhEA, still being similar to the one for beta3 adrenergic
agonist BRL 37344 (Figure 7).
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Figure 7. Alteration of HDL cholesterol in diabetic animals treated with reference substance (BRL 37344) or with deriv-
atives of beta-phenylethylamine compared to diabetic control group * p<0.05; *** p<0.001.




Nondiabetic control  81.74 ± 2.261 0.0002***   <0.0001*** *** 
Diabetic control  166.3 ± 6.793  ***   
BRL 37344 50 mg/kg  77.13 ± 3.639  ns  *** 
A1-βPhEA 20 mg/kg  91.25 ± 4.573  ns  *** 
A2-βPhEA 50 mg/kg  88.01 ± 4.158  ns  *** 
A3-βPhEA 100 mg/kg  90.23 ± 4.643  ns  *** 
A4-βPhEA 100 mg/kg  67.38 ± 8.630  ns  *** 
A5-βPhEA 100 mg/kg  66.32 ± 5.682  ns  *** 
A6-βPhEA 100 mg/kg  66.58 ± 9.860  ns  *** 
A7-βPhEA 100 mg/kg  80.60 ± 3.113  ns  *** 
A8-βPhEA 100 mg/kg  84.24 ± 2.831  ns  *** 
A9-βPhEA 100 mg/kg  87.80 ± 4.384  ns  *** 
A10-βPhEA 100 mg/kg 86.21 ± 2.935  ns  *** 
A11-βPhEA 100 mg/kg 87.86 ± 5.032  ns  *** 
A12-βPhEA 100 mg/kg 84.35 ± 3.656  ns  *** 
A13-βPhEA 100 mg/kg 91.25 ± 6.193  ns  *** 
Table 5. The effect of new derivatives of beta-phenyl ethylamine on serum TG in rats with alloxan-induced diabetes ***
p<0.001.
In Wistar rats alloxan has induced a high increase, statistically significant, of serum triglycer-
ides (TG) (Table 5). Compared to diabetic control group, all the tested compounds have
reduced the values of serum triglycerides with high statistical significance. These effects could
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be due to increased expression [58] of PPARα (liver, kidney, muscle, adipose tissue) and PPAR
γ receptors (subtypes 1, 2, 3 in adipose tissue) resulting in increased expression of the gene for
lipoprotein lipase.
4.1. Effects on body weight
During the research, animals had free access to standard food and water. The body weight was
determined initially, at 48 hours after alloxan administration and then in day 5, 10, and 14 of
the experiment. For nondiabetic control group the same determination were performed as in
the case of diabetic groups. The food was dispensed daily in same amounts and body weight
was determined before the next feeding.
Throughout this determination it was apparent that alloxan-induced diabetes produces, in 48
hours from administration, a statistically nonsignificant reduction (Figure 8) of body weight
in treated animals (203.4 ± 0.7004 vs. 205.9 ± 0.7078).
Figure 8. Body weight of animals initially and at 48 hours after alloxan administration *** p<0.001.
The research results showed that, for diabetic control group, animal body weight increases
after alloxan administration, reaching a significant higher value in day 14 of the experiment
(p = 0.0097**). For the groups treated with reference substance, the body weight varied
statistically nonsignificantly in all moments of determination (Table 6). The amount of
consumed food increased for the diabetic control group, while for the treated groups, it
remained constant. In the determinations of day 14, for nondiabetic control group it was
registered an increase of 1.07% in body weight against the initial measurement, while for the
diabetic control group the increase reached 5.65%. The variation in body weight at the end of
the experiment against initial and compared to diabetic control group was calculated using
the formulas:
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Group Parameter Body weight
basal
Body weight







ND control M ± SE 203.8 ± 3.301 200.2 ± 4.176 204.3 ± 2.894 205.5 ± 2.766 206.0 ± 2.733
ANOVA/48 h 0.7341 ns
D control M ± SE 203.2 ± 3.429 197.0 ± 3.967 206.5 ± 2.363 209.7 ± 2.305 214.7 ± 1.382**
ANOVA/48 h after A 0.0097**
BRL
37344
M ± SE 204.3 ± 2.963 198.7 ± 3.920 203.8 ± 2.868 202.7 ± 2.246 201.5 ± 2.513
ANOVA/48 h after A 0.6778 ns
A1-βPhEA M ± SE 202.5 ± 2.872 197.2 ± 3.640 201.7 ± 2.836 200.8 ± 3.114 199.8 ± 3.092
ANOVA/48 h after A 0.7823 ns
A2-βPhEA M ± SE 200.2 ± 3.781 195.5 ± 4.123 198.5 ± 3.667 198.7 ± 3.556 199.0 ± 3.540
ANOVA/48 h after A 0.9238 ns
A3-βPhEA M ± SE 208.0 ± 2.206 201.8 ± 3.936 206.0 ± 2.145 205.5 ± 2.247 205.0 ± 2.556
ANOVA/48 h after A 0.6202 ns
A4-βPhEA M ± SE 204.8 ± 2.701 199.5 ± 3.805 202.8 ± 2.651 203.2 ± 2.151 202.0 ± 3.088
ANOVA/48 h after A 0.4047 ns
A5-βPhEA M ± SE 207.2 ± 2.868 201.1 ± 4.083 206.0 ± 3.044 204.7 ± 2.552 206.7 ± 3.232
ANOVA/48 h after A 0.6717 ns
A6-βPhEA M ± SE 205.0 ± 2.966 199.1 ± 3.973 203.2 ± 2.868 202.5 ± 2.754 202.0 ± 2.781
ANOVA/48 h after A 0.7505 ns
A7 -βPhEA M ± SE 206.7 ± 2.552 201.1 ± 3.989 204.8 ± 2.358 204.2 ± 2.167 203.7 ± 2.290
ANOVA/48 h after A 0.7213 ns
A8-βPhEA M ± SE 204.8 ± 1.990 201.7 ± 3.802 203.5 ± 1.586 202.7 ± 1.926 203.7 ± 2.290
ANOVA/48 h after A 0.9261 ns
A9 -βPhEA M ± SE 208.2 ± 1.249 202.1 ± 3.667 205.5 ± 0.7638 204.7 ± 1.022 203.8 ± 1.558
ANOVA/48 h after A 0.3638 ns
A10-βPhEA M ± SE 206.3 ± 2.741 200.8 ± 4.036 205.0 ± 2.477 204.8 ± 2.587 204.0 ± 2.671
ANOVA/48 h after A 0.7431 ns
A11-βPhEA M ± SE 208.0 ± 3.066 202.2 ± 4.401 206.2 ± 2.738 205.8 ± 2.713 205.7 ± 2.813
ANOVA/48 h after A 0.7922 ns
A12-βPhEA M ± SE 207.3 ± 2.894 201.7 ± 4.234 205.7 ± 2.565 205.3 ± 2.603 204.5 ± 2.320
ANOVA/48 h after A 0.7561 ns
A13-βPhEA M ± SE 209.3 ± 2.591 203.0 ± 4.244 206.7 ± 2.028 206.7 ± 2.390 205.0 ± 2.266
ANOVA/48 h after A 0.6257 ns
ns, nonsignificant; A, alloxan.
Table 6. The effect of new derivatives of beta-phenylethylamine on body weight in rats with alloxan-induced diabetes
** p<0.01.
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Taking into account that body weight increased for the animals in diabetic control group and
that for all tested substances it has decreased against initial, the effect of the tested substances
was determined compared to diabetic control group (Figure 9). It was therefore noted that
newly synthesized derivatives of beta-phenyl ethylamine and the reference substance BRL
37344 had produced decreases in body weight between 5.89 and 7.76%, compared to diabetic
control animals after 14 days of treatment.
Figure 9. Variation of body weight for animals treated with reference substance and tested substances compared to
diabetic control group at day 14 determination.
5. Conclusions
The results of this experimental research have demonstrated that newly synthesized deriva-
tives of beta-phenylethylamine produce marked biological activity over lipid profile which is
altered in diabetes induced by alloxan administration in rats.
All tested compounds have markedly decreased the values of total cholesterol, LDL choles-
terol, and triglycerides, the effect being more intense than with reference substance BRL 37344.
They also have increased the values of antiatherogenic HDL cholesterol, significantly more
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than the reference substance. Overall, the activity on body weight was of reduction even if the
food consumption of the animals was not altered. These experimental data suggest that the
tested new chemical entities have high therapeutical potential in the treatment of dislipidemias
and/or obesity.
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